# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096159
Filing Date
2024-08-13
Accepted
2024-08-13 16:05:32
Documents
86
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | gyre-20240630.htm iXBRL | 10-Q | 2585359
2 | EX-31.1 | gyre-ex31_1.htm | EX-31.1 | 16415
3 | EX-31.2 | gyre-ex31_2.htm | EX-31.2 | 16329
4 | EX-32.1 | gyre-ex32_1.htm | EX-32.1 | 12322
5 | EX-32.2 | gyre-ex32_2.htm | EX-32.2 | 12316
| Complete submission text file | 0000950170-24-096159.txt |  | 11495060

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | gyre-20240630.xsd | EX-101.SCH | 1513801
89 | EXTRACTED XBRL INSTANCE DOCUMENT | gyre-20240630_htm.xml | XML | 2417971

Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 241201354
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)